Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

Genetic Technology Alert. Drug for Oculopharyngeal Muscular Dystrophy Treatment Receives Orphan Drug Designation; Non-Viral CFTR-Based Gene Therapy for Cystic Fibrosis Patients; Breast Cancer Diagnostic Test in Europe

RELEASE DATE
17-Jul-2015
REGION
Global
Research Code: D757-00-03-00-00
SKU: HC02733-GL-TA_19627

$250.00

Special Price $187.50 save 25 %

In stock
SKU
HC02733-GL-TA_19627

$250.00

$187.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.

Table of Contents

In This Issue

  • 1. DRUG FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY TREATMENT RECEIVES ORPHAN DRUG DESIGNATION
  • 2. NON-VIRAL CFTR-BASED GENE THERAPY FOR CYSTIC FIBROSIS PATIENTS
  • 3. BREAST CANCER DIAGNOSTIC TEST IN EUROPE
  • 4. RECENT PATENTS IN GENETIC TESTS IN THE EUROPEAN UNION
  • 5. TECHVISION 2015
This issue profiles a drug for oculopharyngeal muscular dystrophy treatment that receives orphan drug designation; non-viral CFTR-based gene therapy for cystic fibrosis patients, a breast cancer diagnostic test in Europe.
More Information
No Index No
Podcast No
Industries Healthcare
WIP Number D757-00-03-00-00
Is Prebook No
Ti Codes D758